Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
Ontology highlight
ABSTRACT: This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus PD-0325901 in patients with advanced KRAS mutant (KRASm) non-small cell lung cancer (NSCLC). Part B is designed to perform a randomized comparison of the combination of dacomitinib and PD-0325901 versus standard of care therapy in patients with advanced KRASm NSCLC. It is hypothesized that with this combination strategy the progression free survival of patients with KRASm NSCLC will be doubled.
DISEASE(S): Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2159017 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA